Clinical Scorecard: ApoB Goal Cost-Effective in Primary Prevention

At a Glance

Key Highlights

• ApoB-guided lipid-lowering therapy intensification yielded the greatest quality-adjusted life-year (QALY) gains compared to LDL-C and non–HDL-C targets.
• ApoB strategy prevented the highest number of ASCVD events and was cost-effective with an incremental cost-effectiveness ratio of $30,300 per QALY gained.
• Treatment intensification occurred more frequently with apoB targets (64%) than with non–HDL-C (57%) or LDL-C (51%) targets.

Guideline-Based Recommendations

Diagnosis

• Use apoB measurement to guide lipid-lowering therapy intensification in primary prevention.

Management

• Initiate statin therapy per 2018 AHA/ACC guidelines and intensify treatment to achieve apoB <78.7 mg/dL.
• Consider moderate- and high-intensity statins and ezetimibe to achieve lipid targets.

Monitoring & Follow-up

• Monitor apoB levels to guide treatment adjustments and assess cardiovascular risk reduction.

Risks

• Higher overall costs with apoB strategy are driven by longer life expectancy and extended preventive treatment duration, not by apoB testing costs.
• Model assumptions on treatment effects and costs may influence outcomes.

Patient & Prescribing Data

250,000 statin-eligible, ASCVD-free US adults from NHANES data (2005–2016)

ApoB-guided intensification prevented 1,018 ASCVD events and yielded 1,324 additional QALYs compared with non–HDL-C strategy over a lifetime horizon.

Clinical Best Practices

• Adopt apoB as a primary target for lipid-lowering therapy intensification in primary prevention to maximize ASCVD event reduction and QALY gains.
• Apply treatment intensification thresholds consistent with apoB <78.7 mg/dL to guide therapy adjustments.
• Incorporate cost-effectiveness considerations favoring apoB-guided strategies within a health sector perspective.

References

• JAMA Study on ApoB-guided Lipid-Lowering Therapy